195 related articles for article (PubMed ID: 22249003)
1. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys.
Yamaoka M; Hara T; Hitaka T; Kaku T; Takeuchi T; Takahashi J; Asahi S; Miki H; Tasaka A; Kusaka M
J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):115-28. PubMed ID: 22249003
[TBL] [Abstract][Full Text] [Related]
2. Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.
Petrylak DP; Gandhi JG; Clark WR; Heath E; Lin J; Oh WK; Agus DB; Carthon B; Moran S; Kong N; Suri A; Bargfrede M; Liu G
Invest New Drugs; 2015 Apr; 33(2):397-408. PubMed ID: 25556680
[TBL] [Abstract][Full Text] [Related]
3. Orteronel for the treatment of prostate cancer.
Van Hook K; Huang T; Alumkal JJ
Future Oncol; 2014 Apr; 10(5):803-11. PubMed ID: 24799061
[TBL] [Abstract][Full Text] [Related]
4. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.
Stein MN; Patel N; Bershadskiy A; Sokoloff A; Singer EA
Asian J Androl; 2014; 16(3):387-400. PubMed ID: 24759590
[TBL] [Abstract][Full Text] [Related]
5. CYP17 inhibitors for prostate cancer therapy.
Vasaitis TS; Bruno RD; Njar VC
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):23-31. PubMed ID: 21092758
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer androgen biosynthesis relies solely on CYP17A1 downstream metabolites.
Snaterse G; Taylor AE; Moll JM; O'Neil DM; Teubel WJ; van Weerden WM; Arlt W; Hofland J
J Steroid Biochem Mol Biol; 2024 Feb; 236():106446. PubMed ID: 38104728
[TBL] [Abstract][Full Text] [Related]
7. Adrenal androgens rescue prostatic dihydrotestosterone production and growth of prostate cancer cells after castration.
Wu Y; Tang L; Azabdaftari G; Pop E; Smith GJ
Mol Cell Endocrinol; 2019 Apr; 486():79-88. PubMed ID: 30807787
[TBL] [Abstract][Full Text] [Related]
8. PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer.
Yang Y; Bai Y; He Y; Zhao Y; Chen J; Ma L; Pan Y; Hinten M; Zhang J; Karnes RJ; Kohli M; Westendorf JJ; Li B; Zhu R; Huang H; Xu W
Clin Cancer Res; 2018 Feb; 24(4):834-846. PubMed ID: 29167276
[No Abstract] [Full Text] [Related]
9. HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer.
Almassi N; Reichard C; Li J; Russell C; Perry J; Ryan CJ; Friedlander T; Sharifi N
JAMA Oncol; 2018 Apr; 4(4):554-557. PubMed ID: 29049452
[TBL] [Abstract][Full Text] [Related]
10. Development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum.
Tamae D; Byrns M; Marck B; Mostaghel EA; Nelson PS; Lange P; Lin D; Taplin ME; Balk S; Ellis W; True L; Vessella R; Montgomery B; Blair IA; Penning TM
J Steroid Biochem Mol Biol; 2013 Nov; 138():281-9. PubMed ID: 23851165
[TBL] [Abstract][Full Text] [Related]
11. Non-Classic Disorder of Adrenal Steroidogenesis and Clinical Dilemmas in 21-Hydroxylase Deficiency Combined with Backdoor Androgen Pathway. Mini-Review and Case Report.
Sumińska M; Bogusz-Górna K; Wegner D; Fichna M
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32610579
[TBL] [Abstract][Full Text] [Related]
12. Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormones.
Sakellakis MJ; Hahn AW; Ramachandran S; Zhang M; Hoang A; Song JH; Liu J; Wang F; Basu HS; Sheperd P; Wang X; Frigo DE; Lin SH; Panaretakis T; Zhang J; Navone N; Troncoso P; Logothetis CJ; Titus MA
Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):751-758. PubMed ID: 36100698
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of the Clinically Relevant E305G Mutation in Human P450 CYP17A1.
Liu Y; Grinkova Y; Gregory MC; Denisov IG; Kincaid JR; Sligar SG
Biochemistry; 2021 Nov; 60(43):3262-3271. PubMed ID: 34662099
[TBL] [Abstract][Full Text] [Related]
14. RNA-Seq reveals ACTH-induced steroid hormone pathway participating in goat adrenal gland response to castration.
Jing H; Ding Y; Jiang X; Liu G; Sha Y
Sci Rep; 2023 Aug; 13(1):14025. PubMed ID: 37640763
[TBL] [Abstract][Full Text] [Related]
15. Androgen synthesis cell-specific CREBZF deficiency alters adrenal cortex steroid secretion and develops behavioral abnormalities in adult male mice.
Niu H; Li C; Zhang H; Liu H; Shang C; Jia Y; Wuenjiya ; Li Z; Wang A; Jin Y; Lin P
FASEB J; 2024 May; 38(9):e23650. PubMed ID: 38696238
[TBL] [Abstract][Full Text] [Related]
16. In silico and in vitro assessment of drugs potentially causing adverse effects by inhibiting CYP17A1.
Kędzierski J; Jäger MC; Naeem S; Odermatt A; Smieško M
Toxicol Appl Pharmacol; 2024 May; 486():116945. PubMed ID: 38688424
[TBL] [Abstract][Full Text] [Related]
17. Chronic hypoxia stabilizes 3βHSD1 via autophagy suppression.
Qin L; Berk M; Chung YM; Cui D; Zhu Z; Chakraborty AA; Sharifi N
Cell Rep; 2024 Jan; 43(1):113575. PubMed ID: 38181788
[TBL] [Abstract][Full Text] [Related]
18. Adrenal Steroids and Resistance to Hormonal Blockade of Prostate and Breast Cancer.
Michael P; Roversi G; Brown K; Sharifi N
Endocrinology; 2023 Jan; 164(3):. PubMed ID: 36580423
[TBL] [Abstract][Full Text] [Related]
19. Modulation of higher-primate adrenal androgen secretion with estrogen-alone or estrogen-plus-progesterone intervention.
Conley AJ; Stanczyk FZ; Morrison JH; Borowicz P; Benirschke K; Gee NA; Lasley BL
Menopause; 2013 Mar; 20(3):322-8. PubMed ID: 23435030
[TBL] [Abstract][Full Text] [Related]
20. Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors.
Bonomo S; Hansen CH; Petrunak EM; Scott EE; Styrishave B; Jørgensen FS; Olsen L
Sci Rep; 2016 Jul; 6():29468. PubMed ID: 27406023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
